



— 16 —  
WORLD CONGRESS  
OF GYNECOLOGICAL  
ENDOCRINOLOGY ♀  
IV CONGRESSO ISGE ITALIA



MARCH 5-8 2014  
FIRENZE ITALY

[WWW.ISGESOCIETY.COM/ISGE2014](http://WWW.ISGESOCIETY.COM/ISGE2014)

PRELIMINARY PROGRAMME

**DEAR FRIENDS,** On behalf of the Executive Committee of the International Society of Gynecological Endocrinology, it is my great pleasure to invite you to join the 16<sup>th</sup> World Congress of Gynecological Endocrinology that will be held in Florence from the 5<sup>th</sup> to 8<sup>th</sup> March 2014.

Our biennial meeting can be considered the major event in developing, upgrading and teaching the Gynecological Endocrinology. Our Discipline, strongly stimulated by the possibilities offered by molecular and cellular endocrinology and by the progress in clinical biochemistry and experimental pharmacology, needs this important moment, which can be considered our World Congress. In the same way, the achievements of randomized clinical trials, epidemiological surveys and large meta-analysis will allow us to better understand the possibilities, limits, risks and advantages of our therapies and diagnostic approaches.

The programme, developed by the Executive Board, will receive input from Scientific Societies, mostly members of the Fisce, that normally cooperates with us.

Moreover, the Congress remains open to the suggestions of our Members, Working groups and any other Institution that want to increase the scientific and educational level of the Event.

In the meantime, the ISGRE will activate since 2013 the Winter and Summer Schools, to promote the continuous medical education and up-dating in Gynecological and Reproductive Endocrinology

I strongly hope to receive your proposals for the progress of our Society, and have the pleasure to meet you in Florence in March 2014.

Andrea R. Genazzani  
President of ISGE



**EXECUTIVE COMMITTEE  
2010-2014**

#### **PRESIDENT**

A.R.GENAZZANI PISA, ITALY

#### **TREASURER**

B.LUNENFELD TEL-AVIV, ISRAEL

#### **EXECUTIVE SECRETARY**

T.SIMONCINI PISA, ITALY

#### **MEMBERS**

F.AL-AZZAWI LEICESTER, UK

S.BERGA ATLANTA, USA

M.BIRKHAUSER BERN, SWITZERLAND

P.BOUCHARD PARIS, FRANCE

M.BRINCAT MALTA

N.R. DE MELO SAO PAULO, BRAZIL

L.DEVOTO SANTIAGO, CHILE

J.M.FOIDART LIEGE, BELGIUM

P.KENEMANS AMSTERDAM, NL

T.MARUO KOBE, JAPAN

M.MENDELSON BOSTON, USA

A.MILEWICZ WROCLAW, POLAND

F.NAFTOLIN NEW YORK, USA

E.H.Y.NG HONG KONG, CHINA

F.PETRAGLIA SIENA, ITALY

A.SCHINDLER ESSEN, GERMANY

C.SIMON VALENCIA, SPAIN

E.SIMPSON CLAYTON, AUSTRALIA

N.SISELES BUENOS AIRES, ARGENTINA

V.SMETNIK MOSCOW, RUSSIA

B.TARLATZIS THESSALONIKI, GREECE

B.Von SCHOULTZ STOCKHOLM, SWEDEN

#### **ORGANIZING SECRETARIAT**

**Biomedical Technologies srl**

[www.biomedicaltechnologies.com](http://www.biomedicaltechnologies.com)

**Main Office and Accounting**

**Department**

Via P. Cugia 1 - 09129

Cagliari - Italia

T. +39 070340293

F. +39 070307727

[isge2014@btcongress.com](mailto:isge2014@btcongress.com)

**Marketing Office**

T. +39 068546198

F. +39 0685389063

[marketing@btcongress.com](mailto:marketing@btcongress.com)

#### **HOTEL BOOKING**

See the Congress website

For group enquires please contact

[info@btcongress.com](mailto:info@btcongress.com)

#### **CONGRESS WEBSITES**


[www.isgesociety.com/isge2014](http://www.isgesociety.com/isge2014)

[www.isgesociety.com](http://www.isgesociety.com)

#### **SCIENTIFIC SECRETARIAT**

[isge@tiscali.it](mailto:isge@tiscali.it)

 [www.twitter.com/gynendo](https://twitter.com/gynendo)

 [www.facebook.com/gynendo](https://www.facebook.com/gynendo)

# THE 16TH ISGE WORLD CONGRESS

The Congress will be organized in **Plenary Lectures, Debates and Plenary Sessions**. Each session will include four or five speakers each presenting his scientific research in approximately 20 minutes plus 5 minutes discussion. Moreover, **Special Sessions** on Last Minute Hot Topics, **Sponsored Symposia, Round Tables**, Oral Presentations and Poster Sessions will be available.

**SCIENTIFIC SOCIETIES SYMPOSIA**  
Scientific Societies members of the FISGE and any other scientific society operating in our field may propose an entire symposium at their own cost, suggesting titles, presentations, speakers and chairmen. The Executive Committee will examine the proposals for inclusion in the scientific programme with the possibility to include one extra speaker or a chairman of its choice. The deadline for submission is **November 18<sup>th</sup> 2013**.

**OFFICIAL LANGUAGES AND SIMULTANEOUS TRANSLATION**  
English is the official language of the congress, and all lectures must be held in English. Simultaneous translation into other languages will be evaluated on the basis of the number of request for each language.

**PRE-CONGRESS COURSES**  
Two Pre-Congress Courses organized by ISGRE will take place on Wednesday 5<sup>th</sup>.

HALLS▶	AUDITORIUM	AFFARI 0	AFFARI 1	AFFARI 2	VERDE	ONICE
<b>Wednesday, March 5<sup>th</sup></b>						
					Pre-Congress Courses	
15.00-17.00	Opening Symposium					
17.30-19.15	Opening Ceremony					
19.15-19.45	Opening Lecture					
<b>Thursday, March 6<sup>th</sup></b>						
08.30-09.30	SciSoc/OP	SciSoc/OP	SciSoc/OP	SciSoc/OP	SciSoc/OP	SciSoc/OP
09.45-11.15	PS	PS	PS	CME Course	PS	SciSoc/OP
11.15-11.45	Visit to the Exhibition Area			(9.45-13.15)		
11.45-13.15	PS	PS	PS		PS	SciSoc/OP
13.15-15.15		LS	LS			
15.15-15.45	Visit to the Exhibition Area					
15.45-16.15	PL			PL	PL	
16.30-18.00	PS	PS	PS	PS	PS	SciSoc/OP
18.00-19.00					ISGE Assembly	
<b>Friday, March 7<sup>th</sup></b>						
08.30-09.30	SciSoc/OP	SciSoc/OP	SciSoc/OP	SciSoc/OP	SciSoc/OP	SciSoc/OP
09.45-11.15	PS	PS	PS	CME Course	PS	SciSoc/OP
11.15-11.45	Visit to the Exhibition Area			(9.45-13.15)		
11.45-13.15	PS	PS	PS		PS	SciSoc/OP
13.15-15.15		LS	LS			
15.15-15.45	Visit to the Exhibition Area					
15.45-16.15	PL			PL	PL	
16.30-18.00	PS			PS	PS	SciSoc/OP
18.00-20.00	Poster Session					
<b>Saturday, March 8<sup>th</sup></b>						
08.30-10.00	PS	PS	PS	CME Course	PS	SciSoc/OP
10.15-11.15		DB/MTE	DB/MTE	(9.45-13.15)	DB/MTE	SciSoc/OP
11.15-11.45	Visit to the Exhibition Area					
11.45-13.15	PS	PS	PS		PS	SciSoc/OP
13.15-15.15		LS	LS			
15.45-16.15				PL	PL	
16.30-18.00		PS	PS	PS	PS	SciSoc/OP
18.00-19.30		PS	PS	PS	PS	SciSoc/OP
19.30-20.00		Closing Cer.				

**PS** Plenary Session/Symposia

**DB/MTE** Debate - Meet The Expert

**LS** Lunch Symposium

**PL** Plenary Lecture

**SciSoc/OP** Scientific Soc. or Oral Presentations

# SCIENTIFIC PROGRAMME

## Plenary Lectures

- Kenemans Peter (NL)** Women's Health and Women's Rights
- Schenker Joseph (IL)** Ovarian Stimulation of Patients in Risk of OHSS
- Sitruk-Ware Regine (USA)** Emerging Science & Technology for Contraception, an answer to decreasing maternal mortality?
- Pecorelli Sergio (IT)** Innovative Drugs: new perspectives and health system sustainability
- Archer David (USA)** The Optimal Time to Stop Hormone Therapy

## Debates on Hot Topics

### 01. SELECTING THE RIGHT CONTRACEPTIVE STRATEGY

- Gemzell-Danielsson Kristina (SW)** Contraception for young and nulliparous women
- Serfaty David (FR)** Contraception and compliance: MID-LARC or LARC for young women?

### 02. ULTRASOUND IN EARLY PREGNANCY

- Goldstein Steven R. (USA)** Early Pregnancy: Is it time to rethink our Ultrasound criteria?
- Luchi Carlo (IT)** First trimester ultrasound: Is it the moment to change the future?

## PLENARY SESSIONS

### 01. HORMONES AND BREAST CANCER

- Mueck Alfred (D)** Biochemistry of estrogen metabolism – genotoxic or protective in the breast?
- Brincat Mark (MT)** Reducing Breast Cancer rates using Pharmacological Intervention at the time of the Menopause
- Simpson Evan (AUS)** Obesity and breast cancer: a tale of inflammation and dysregulated metabolism.

### 02. NEUROENDOCRINE REGULATION OF THE GONADAL AXIS

- Meczekalski Blazej (PL)** Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations
- Castelo-Branco Camil (ES)** Sensineural changes in congenital hypogonadism
- Berga Sarah (USA)** Stress, Rank, and Obesity: Understanding the Reproductive Consequences of Obesity
- Lunenfeld Bruno (IL)** 100 years from the discovery of the hypothalamic- pituitary gonadal axis- What did we learn?

### 03. PROGESTERONE, PROGESTINS AND PROGESTERONE RECEPTOR INTERACTIONS

- Schindler Adolf (D)** The clinical relevance of classification and comparative pharmacology of progestogens
- Ruan Xiangyan (ROC)** Membrane-bound progestogen receptors – importance for breast cancer Development
- Sitruk-Ware Regine (USA)** Potential health benefits of Progesterone

### 04. NEW CHALLENGES IN BREAST CANCER MANAGEMENT

- Biglia Nicoletta (IT)** Fertility preservation and pregnancy after breast cancer. When and how.
- Von Schoultz Bo (SW)** Can we minimize the risks of HRT after Breast cancer?
- Gompel Anne (FR)** Glucocorticoid receptor and breast cancer

### 05. FEMALE SEXUAL DYSFUNCTION: ENDOCRINE AND CULTURAL ASPECTS

- Nappi Rossella E. (IT)** To Sex or not to Sex in women taking hormonal contraception
- Bitzer Johannes (CH)** Painful sex – where does it come from and how to help
- Lachowsky Michele (FR)** Sexuality to-day, intimacy or performance?

### 06. ENDOMETRIOSIS: NEW CHALLENGES FROM BASIC SCIENCE

- Kiesel Ludwig (D)** Regulation of endometriosis by miRNA
- Petraglia Felice (I)** Molecular aspects of deep infiltrating endometriosis
- Taylor Robert (USA)** Mechanisms of Inflammation and Pain in Endometriosis
- Pluchino Nicola (IT)** Effects on sexual function of medical and surgical therapy for endometriosis

### 07. REPRODUCTIVE RECONSTRUCTIVE SURGERY

- Adamyán Leila (RUS)** New trends in reproductive reconstructive surgery
- Creatsas George (GR)** Reconstruction of uterovaginal anomalies
- Fedele Luigi (IT)** Obstructive genital malformations

### 08. ENDOMETRIUM AND MENHORRAGIA

- Goldstein Steven R. (USA)** The Endometrium: when it bleeds and when it doesn't
- Bouchard Philippe (FR)** SPRM and uterine bleeding
- Sciarra John J. (USA)** New Treatments for Fibroids

### 09. MEDICALLY-ASSISTED PROCREATION: THE CLINICAL IMPACT

- Barri Pedro (ES)** Use of androgens in ART. Fiction or reality
- Artini Paolo G. (IT)** Change of gene expression profiles of cumulus cells obtained during different IVF protocol of stimulation
- Tarlatzis Basil (GR)** The role of pre-ovulatory progesterone rise in hyper and hypo responders st choice)
- Hourvitz Ariel (IL)** Understanding In-Vivo Oocyte Maturation-Improving In Vitro Maturation (IVM)

### 10. ENDOCRINE DISORDERS AND ADOLESCENCE: THE IMPACT FOR FERTILE LIFE

- Bruni Vincenzina (IT)** Primary ovarian insufficiency in very young women
- Sultan Charles (FR)** From genes to clinics management of adolescent hyperandrogenism
- Birkhaeuser Martin (CH)** Delayed puberty: impact on fertility



### 11. OLD AND NEW STRATEGIES FOR CONTRACEPTIVE CARE

**Foidart Jean Michel (B)** Haemostasis and estetrol containing oral contraceptives

**Volpe Annibale (IT)** More benefits with new strategies in hormonal contraception

**De Melo Nilson (BR)** Title to be defined.

### 12. OVARIAN FUNCTION AND AGEING

**Devoto Luigi (RCH)** Neuroendocrinology of ovarian aging  
**Fausser Bart C. (NL)** AMH: implications of ovarian reserve assessment

**Benedetto Chiara (IT)** Ovarian Tissue Cryo-storage and Transplantation for patients at high risk of Ovarian Failure.

**Donnez Jacques (B)** Ovarian freezing: the anti ageing therapy of the future?

### 13. VITAMIN D: A NEW HORMONE IN REPRODUCTIVE MEDICINE

**Milewicz Andrzej (PL)** PCOS and Vit.D and its receptors gene polymorphisms

**Perez-Lopez Faustino (ES)** Vitamin D during pregnancy

**Brincat Mark (MT)** Vit D in the prevention of Osteoporosis, alone or on Combination

### 14. METABOLIC SYNDROME AND OBESITY: IMPACT ON REPRODUCTION AND AGEING

**Naftolin Frederick (USA)** A developmental basis for the Metabolic Syndrome

**Lanzone Antonio (IT)** Impact of PCOS phenotypes on metabolic and reproductive function

**Genazzani Alessandro D. (IT)** Obesity and Metabolic Syndrome: impact and relationship with menopausal transition

### 15. BRAIN, MOOD AND COGNITION: THE HORMONAL IMPACT

**Linden-Hirshberg Angelica (SW)** Effects of testosterone and estrogen treatment on the serotonin system in the brain of postmenopausal women

**Genazzani Andrea R. (IT)** Sex steroids impact on brain Allopregnanolone

**Rocca Walter (USA)** Oophorectomy, estrogen, and cognitive aging: a 2014 update

**Maki Pauline (USA)** Effects of Stellate Ganglion Block on Vasomotor Symptoms, Cognition, and Mood: Findings from a Randomized Clinical Trial

### 16. STEM CELLS IN OVARY, ENDOMETRIUM AND BONE

**Tilly Jonathan L. (USA)** Oocyte-producing Stem Cells in Adult Human Ovaries: Biology and Clinical Implications

**Simon Carlos (ES)** Endometrial Reconstruction from Stem Cells

**Al-Azzawi Farook (GB)** Sexual dimorphism of stem cell behavior - the gonads and the brain

### 17. MOLECULES AND RECEPTORS FOR BONE HEALTH AND OSTEOPOROSIS PREVENTION

**Smetnik Vera (RUS)** Hormonal and genetic status in amenorrheic and postmenopausal patients with low bone mineral density

**De Villiers Tobias (SA)** The revival of estrogen as an agent in the prevention of osteoporotic fractures

**Palacios Santiago (ES)** Osteoporosis Sequential Training

### 18. MENOPAUSE, AGEING AND CARDIOVASCULAR RISKS

**Simoncini Tommaso (IT)** Endothelial dysfunction and prenatal programming of cardiovascular risk

**Mikkola Tomi (FIN)** Postmenopausal hormone therapy and cardiovascular mortality - nationwide register study from Finland

**Siseles Nestor (RA)** Cardiovascular health in menopausal woman: when to begin the hormone treatment?

### 19. NEW PERSPECTIVES ON PREMATURE OVARIAN INSUFFICIENCY

**Vujovic Svetlana (RSB)** Premature Ovarian Insufficiency: fertility challenge

**Panay Nick (UK)** Premature Ovarian Insufficiency database: progress in global collaboration

**Ng Ernest Hung Yu (PRC)** Use of DHEA in primary ovarian insufficiency

### 20. WOMEN'S HEALTH THROUGH AGEING

**Rees Margaret (UK)** Managing the menopause without estrogen

**Archer David (USA)** Estrogen and Selective Estrogen Receptor Modulators for Menopausal Symptoms

**Cano Antonio (ES)** Personalized medicine and disease prevention after menopause: a window of opportunity for lifestyle.

### 21. OVARIAN CANCER: THE ULTIMATE CHALLENGE

**Cibula David (CZ)** New paradigm in surgical treatment of ovarian cancer

**Morice Philippe (FR)** Fertility and borderline ovarian tumor: conservative management, risk of recurrence and alternative options

**Gadducci Angiolo (IT)** Fertility after conservative treatment of malignant germ cell tumors of the ovary

**Konishi Ikuo (JP)** Ovarian cancer in endometriosis: Clinical and molecular aspects

### 22. PLACENTAL DEVELOPMENT: PATOPHYSIOLOGY AND CLINICAL IMPACT

**Maruo Takeshi (J)** Relaxin and corticotropin-releasing hormone in the angiogenesis

**Reiter Russel J. (USA)** Placental Melatonin: Implications for Pregnancy and Gynecology

**Taylor Robert (USA)** Decidual Dysfunction and Implantation Failure

**Martinelli Pasquale (IT)** Placenta accreta: a iatrogenic uterine disease



### 23. UNDERSTANDING AND TREATING FETAL GROWTH RESTRICTION

**Todros Tullia (IT)** Small, but otherwise normal fetuses are really normal?

**Challis John (CDN)** Effects of glucocorticoids on fetal growth and development

**Ferrazzi Enrico M. (IT)** The role of umbilical vein blood flow volume measurements in IUGR fetuses

### 24. HYPERTENSIVE DISORDERS IN PREGNANCY: FROM THE BENCH TO THE BEDSIDE

**Chedraui Peter (EQ)** The utility of biochemical markers in the prediction of preeclampsia

**Valensise Herbert (IT)** Long term effects of preeclampsia on maternal health

**Lyall Fiona (UK)** Placental stress and hypertensive disorders of pregnancy

### 25. CATAMENIAL HEADACHE, PREMENSTRUAL SYNDROME, AND POST TRAUMATIC DISORDERS: THE DARK SIDE OF THE MOON

**Facchinetti Fabio (IT)** The issue of menstrual migraine today

**Studd John (UK)** Suppression of Ovulation in the Treatment of Severe Premenstrual Syndrome

**Maki Pauline M. (USA)** Elevated symptoms of post-traumatic stress disorder during the menopausal transition

### 26. ENDOSCOPIC SURGERY: IMPACT ON FERTILITY AND QUALITY OF LIFE

**Mettler Liselotte (D)** New concepts of hysterectomies and alternative methods

**Cela Vito (IT)** Robotic treatment of deep endometriosis

**Angioni Stefano (IT)** Radical excisional surgery in deep endometriosis. Is it the best approach to improve quality of life?

## REGISTRATION FEES

REGISTRATION FEES (VAT INCLUDED)	Until 18/10/2013	Until 13/01/2014	After 13/01/2014	On site
Isge Member Delegate	€ 400,00	€ 550,00	€ 650,00	€ 700,00
Delegate	€ 500,00	€ 650,00	€ 750,00	€ 800,00
Isge Member from Developing Countries	€ 350,00	€ 500,00	€ 600,00	€ 650,00
Developing Countries	€ 400,00	€ 550,00	€ 650,00	€ 700,00
Isge Member Technical Delegate*	€ 250,00	€ 350,00	€ 450,00	€ 500,00
Technical Delegate*	€ 300,00	€ 400,00	€ 500,00	€ 550,00
-34 Competition Participant**	€ 200,00	€ 300,00	€ 400,00	€ 450,00

\*Residents in training, nurses and technicians. Official certificate must be submitted.

\*\*Participants and winners list will be published on [www.isgesociety.com/isge2014](http://www.isgesociety.com/isge2014) by October 10<sup>th</sup> 2013

### REGISTRATION FEE FOR THE DELEGATE INCLUDES

- ◆ CONGRESS KIT
- ◆ ACCESS TO ALL SESSIONS AND EXHIBITION AREA
- ◆ ABSTRACTS CD
- ◆ 2 YEARS ISGE MEMBERSHIP
- ◆ CME CREDITS
- ◆ OPENING AND CLOSING CEREMONIES

### CANCELLATION POLICY FOR REGISTRATION

Refunds (less € 25,00 for taxes and administrative expenses) will be granted to delegates unable to attend. A written notice must be received by the Organizing Secretariat before February 1<sup>st</sup> 2014.

No refunds will be made for cancellations received after February 1<sup>st</sup> 2014. All refunds will be issued after the Congress.

### HOW TO REGISTER

Registration is only possible online filling out the registration form on [www.isgesociety.com/isge2014](http://www.isgesociety.com/isge2014). Payment will be accepted by bank transfer, credit card or PayPal.

	One Year (2013)	Two Years (2013-2014)
Subscription to the printed edition of Gynecological Endocrinology	€ 105,00	€ 190,00

\* special price together with the congress registration

### GROUPS REGISTRATION

Companies and Agencies must send the list of their registrants including all personal data as indicated on the registration form. The Organizing Secretariat can provide a sample excel file to be filled out and emailed to [isge2014@btcongress.com](mailto:isge2014@btcongress.com). Accommodation can be accepted only upon pre-registration.

### INSURANCE

The Congress Organizers will not accept any liability for personal injury, or loss/damage to property, belongings of meeting participants or accompanying persons, either during or as a result of the Congress or during their stay in Florence. It is, therefore, recommended that participants arrange their own personal health, accident and travel insurance.

# ABSTRACTS

## ABSTRACTS SUBMISSION INSTRUCTIONS AND GUIDELINES GENERAL POLICIES

In order to send an abstract you have to create for free your personal congress account. This will allow you to interact with the congress organization (both scientific and organizing secretariat) and satisfy all your possible needs regarding abstract submission, registration, hotel booking, etc.

1. Deadline for abstract submission is **November 25<sup>th</sup> 2013 (September 29<sup>th</sup> for the Under 34 competition)**

2. Each person is allowed to submit a maximum of two abstracts as presenting author: one oral presentation and one poster or, alternatively, two posters. There is no limit to the number of abstracts submitted as co-author.

3. Presenting authors will be notified whether their abstracts are accepted by **December 23<sup>th</sup> 2013**.

4. Further details on the schedule and instructions for oral and poster presentations will be sent to the presenting authors later.

The Scientific Programme of the Congress will be available on [www.isgesociety.com/isge2014](http://www.isgesociety.com/isge2014) by **February 2014**.

5. Authors, whose abstracts have been accepted, must register for the Congress and pay the registration fee by **January 13<sup>th</sup> 2014**.

**Failure to do so will result in exclusion from the programme and the Abstract edition.**

6. Abstracts can only be submitted using the on-line form available on [www.isgesociety.com/isge2014](http://www.isgesociety.com/isge2014).

A guideline will help you in filling out the form. Abstracts submitted via email or fax will not be accepted.

**If you have any queries about your poster or presentation please contact the scientific secretariat**



# PRIZES

UNDER 34  
RESEARCHERS HAVE  
THE POSSIBILITY  
TO WIN CONGRESS  
REGISTRATION AND  
ACCOMMODATION,

## UNDER 34 COMPETITION

Participants must be **under the age of 34 by March 5<sup>th</sup> 2014** and can submit a maximum of 2 abstracts as first author on any of the Congress' topics by **September 29<sup>th</sup>, 2013** using the online form and checking the apposite box.

- ◆ **The first authors of the 100 better works** will receive a voucher for free registration and accommodation in a 3 stars hotel (twin accommodation).
- ◆ **The first authors of the remaining accepted abstracts** not ranked among the first 100 will pay the registration to the Congress €200 or €300 if payed after 18/01/2013 (instead of €750).
- ◆ **The first 4 best ranked authors** will have the opportunity to present their abstract during a Plenary Session as a Main Speaker.

## POSTER AWARDS

Four posters will be awarded each with a free registration to the next ISGE Congress including a free accommodation for one person (overnight stay in a 3 stars hotel - twin accommodation). The awards will be given during the Closing Ceremony on Saturday March 8<sup>th</sup>.

THE BEST POSTERS  
WILL BE AWARDED

## IMPORTANT DATES

29/09/2013

Abstracts submission for the under 34 competition

18/10/2013

Early bird registration

18/11/2013

Symposia proposal

25/11/2013

Abstracts submission

13/01/2014

Reduced rate registration



## TOPICS FOR ORAL PRESENTATIONS AND POSTERS

**1. GYNECOLOGICAL  
ENDOCRINOLOGY**

- 1.1 Regulation of the HPA axis
- 1.2 FSH and LH receptors
- 1.3 Hyperprolactinemia
- 1.4 GnRH analogues and antagonists
- 1.5 Steroids and steroid receptors signaling mechanisms
- 1.6 Biological actions of progestins
- 1.7 Androgens and hyperandrogenisms
- 1.8 Primary and secondary amenorrhea
- 1.9 Polycystic ovary syndrome
- 1.10 Insulin resistance
- 1.11 Obesity, metabolic syndrome and women's health
- 1.12 Pediatric and adolescent gynecology
- 1.13 Thyroid diseases
- 1.14 Endocrine disorders and woman's health
- 1.15 Endocrine disruptors
- 1.16 Selective steroid receptor modulators

**2. CONTRACEPTION**

- 2.1 New compounds for contraception
- 2.2 Non-contraceptive benefits of contraceptives
- 2.3 Male contraception
- 2.4 Emergency contraception
- 2.5 Medical and surgical abortion
- 2.6 Intrauterine contraceptives
- 2.7 Contraception and adolescents
- 2.8 Contraception and perimenopause
- 2.9 Therapeutic uses of hormonal contraceptives
- 2.10 Long lasting contraception

**3. MEDICALLY ASSISTED  
PROCREATION**

- 3.1 Embryo implantation and development
- 3.2 Stem cells and human reproduction
- 3.4 Mechanisms of follicle selection and development
- 3.5 Reproduction, the Immune system and oxidative stress
- 3.6 The infertile couple
- 3.7 Techniques in medically

- assisted procreation
- 3.8 Ovulation induction
- 3.9 Ovarian hyperstimulation
- 3.10 Endometriosis and assisted reproduction
- 3.11 The anovulatory patient
- 3.12 Endocrine disorders and medically assisted procreation
- 3.13 Adnexal diseases and medically assisted procreation
- 3.14 Fertility preservation
- 3.15 Autologue and heterologue donation
- 3.16 MAP and ethics
- 3.17 MAP in premature ovarian insufficiency

**4. OBSTETRICS**

- 4.1 Recurrent abortion
- 4.2 Extra-uterine pregnancy
- 4.3 Prenatal diagnosis
- 4.4 Prenatal medicine
- 4.5 The placenta and the fetal membranes
- 4.6 The thyroid and pregnancy
- 4.7 Immunological disorders and pregnancy
- 4.8 Endocrine disorders in pregnancy
- 4.9 Neurodegenerative disorders in pregnancy
- 4.10 Insulin resistance and obstetric diseases
- 4.11 Obesity and fetal and maternal risks
- 4.12 Pregnancy and lifestyle
- 4.13 Preterm labor and delivery
- 4.14 Gestational hypertension, pre-eclampsia and eclampsia
- 4.15 High risk pregnancy: diagnosis and management
- 4.16 Normal and abnormal intrauterine growth
- 4.17 Infectious diseases and pregnancy
- 4.18 Twin and multiple pregnancies
- 4.19 Labor induction
- 4.20 Caesarean Section: pro and con
- 4.21 Fetal origins of adult diseases
- 4.22 Postpartum management of high risk pregnancies

**5. GYNECOLOGY**

- 5.1 Stem cells in gynecology
- 5.2 Angiogenesis and

- gynecological diseases
- 5.3 Puberty and adolescent gynecology
- 5.4 Female sexual function and dysfunction
- 5.5 Sexually transmitted diseases
- 5.6 Hormones and gynecological disorders
- 5.7 Endometrial regulation
- 5.8 Abnormal uterine bleeding
- 5.9 Pelvic pain
- 5.10 Endometrial hyperplasia
- 5.11 Endometriosis: genetics and hormones
- 5.12 Medical treatments for endometriosis
- 5.13 Uterine myomas, medical and surgical management
- 5.14 Clinical management of simple adnexal cysts
- 5.15 Vulvar and vaginal lesions

**6 MENOPAUSE AND AGEING**

- 6.1 Steroid hormones and ageing
- 6.2 Neurotoxicity, neuronal survival and hormone protection
- 6.3 The climacteric syndrome
- 6.4 Menopause, HRT and cardiovascular disease
- 6.5 Menopause, HRT and cancers
- 6.6 Menopause, HRT and neurodegenerative diseases
- 6.7 Postmenopausal osteoporosis
- 6.8 Bisphosphonates, PTH and the bone-forming agents
- 6.9 Selective estrogen receptor modulators
- 6.10 Progesterone and progestins
- 6.11 Androgen therapy
- 6.12 Non-hormonal treatments for climacteric women
- 6.13 Sexual health and dysfunction

**7 GYNECOLOGICAL ONCOLOGY**

- 7.1 Genes and gynecological cancers
- 7.2 Hormones and gynecological cancers
- 7.3 Stem cells and gynecological malignancies
- 7.4 Proteomics for cancer diagnosis and treatment
- 7.5 Screenings and for gynecological cancers
- 7.6 HPV and HPV vaccines

- 7.7 Border-line and pre-tumoral lesions
- 7.8 Clinical management of gynecological cancers
- 7.9 Conservative approaches to gynecological cancers
- 7.10 New concepts in radio/chemotherapy
- 7.11 Hormonal therapies for gynecological cancers
- 7.12 Pregnancy and cancer

**8 THE BREAST**

- 8.1 Breast development and function
- 8.2 Hormones and the breast
- 8.3 Benign breast diseases, contraception and HRT
- 8.4 Breast carcinogenesis
- 8.5 Hormones, breast cell proliferation and metastasis
- 8.6 New prognostic and predictive factors
- 8.7 Anti-estrogens, SERMs and aromatase inhibitors
- 8.8 Oncological and aesthetic breast surgery
- 8.9 Breast cancer and pregnancy

**9 GYNECOLOGICAL SURGERY**

- 9.1 Vaginal approaches to pelvic diseases
- 9.2 Urinary incontinence
- 9.3 New techniques for pelvic floor defects correction
- 9.4 Laparoscopic treatment of pelvic masses
- 9.5 Laparoscopy, endometriosis and reproduction
- 9.6 New treatments of uterine myomas
- 9.7 Sentinel node biopsy in gynecological cancers
- 9.8 Oncological applications of laparoscopy
- 9.9 Robotic surgery in gynecology
- 9.10 Multidisciplinary approach to the pelvic floor

**10 DIAGNOSIS**

- 10.1 Ultrasound in gynecology and obstetrics
- 10.2 Interventional ultrasound techniques
- 10.3 Hysteroscopy
- 10.4 Colposcopy